Molecular biomarkers for cancer detection in blood and bodily fluids.
Cancer is a major and increasing public health problem worldwide. Traditionally, the diagnosis and staging of cancer, as well as the evaluation of response to therapy have been primarily based on morphology, with relatively few cancer biomarkers currently in use. Conventional biomarker studies have been focused on single genes or discrete pathways, but this approach has had limited success because of the complex and heterogeneous nature of many cancers. The completion of the human genome project and the development of new technologies have greatly facilitated the identification of biomarkers for assessment of cancer risk, early detection of primary cancers, monitoring cancer treatment, and detection of recurrence. This article reviews the various approaches used for development of such markers and describes markers of potential clinical interest in major types of cancer. Finally, we discuss the reasons why so few cancer biomarkers are currently available for clinical use.
Feng
Qinghua
Q
Department of Pathology, School of Medicine, University of Washington, Seattle, Washington 98109, USA. qf@u.washington.edu
Yu
Mujun
M
Kiviat
Nancy B
NB
D000912:Antibodies, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D001826:Body Fluids / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000235:genetics; D044127:Epigenesis, Genetic; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000378:metabolism; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D020641:Polymorphism, Single Nucleotide; D012334:RNA, Neoplasm / Q000235:genetics
D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D012334:RNA, Neoplasm